OKUR
OnKure Therapeutics, Inc.3.0200
-0.1800-5.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
40.92MP/E (TTM)
-Basic EPS (TTM)
-4.68Dividend Yield
0%Recent Filings
10-K
FY2025 results
OnKure Therapeutics posted FY2025 net losses of $59.5M, up from $52.7M in FY2024, driven by ramped R&D to $48.3M (from $43.8M) for PIKture-01 Phase 1 enrollment completion in monotherapy/fulvestrant arms and triplet initiations in Q4, while G&A rose to $14.7M amid public company costs. Cash burned $51.8M in operations, leaving $59.1M at year-end—enough into Q4 2026 yet raising going concern doubts without fresh capital. Q4 momentum shone in PIKture-01 expansions, but no revenue or EPS data disclosed. PIKture-01 data readout slated for 2026. Clinical trial delays threaten quarterly progress.
8-K
Q4 loss narrows, cash $59M
OnKure Therapeutics reported Q4 2025 net loss of $13.5M, down from $17.4M last year, with cash at $59.1M as of December 31. R&D expenses dropped to $10.7M from $14.4M, reflecting lower clinical and manufacturing costs. Cash burn accelerates. PIKture-01 trial data and next-gen PI3Kα inhibitor arrive this month.
10-Q
Q3 FY2025 results
OnKure Therapeutics posted a Q3 operating loss of $15.5M, up 35% y/y from $11.5M (derived), driven by higher R&D at $11.9M (up 18%) and G&A at $3.6M (up 157%), fueled by $3.0M share-based comp. YTD net loss hit $46.0M on $48.8M opex, with cash burn of $40.3M from operations leaving $70.3M in cash equivalents at quarter-end September 30, 2025—enough for 12 months. No revenue yet; post-October 2024 merger with Reneo (no goodwill recognized), Legacy OnKure's books prevail. Cash is king here.
8-K
ATM sales agreement signed
8-K
Q3 loss widens; trial data Q1 2026
OnKure Therapeutics reported Q3 2025 net loss of $14.7 million, up from $11.6 million last year, with R&D expenses rising to $11.9 million amid PIKture-01 trial advances. First patients dosed in triplet arms combining OKI-219 with fulvestrant/ribociclib and trastuzumab/tucatinib; data from monotherapy, doublet, and triplets now due Q1 2026. Cash at $70.3 million funds operations into Q4 2026. Clinical momentum builds.
IPO
Employees
Sector
Industry
AURA
Aura Biosciences, Inc.
6.18-0.15
KURA
Kura Oncology, Inc.
10.63+0.07
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MURA
Mural Oncology plc
2.04+2.04
NXTC
NextCure, Inc.
11.12-0.35
OKYO
OKYO Pharma Limited
1.88-0.01
ONCY
Oncolytics Biotech Inc.
1.04+0.12
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
XCUR
Exicure, Inc.
6.06+0.33